Profile data is unavailable for this security.
About the company
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
- Revenue in USD (TTM)4.51m
- Net income in USD-7.66m
- Incorporated1981
- Employees13.00
- LocationInMed Pharmaceuticals Inc1445-885 West Georgia St.VANCOUVER V6C 3E8CanadaCAN
- Phone+1 (604) 669-7207
- Fax+1 (778) 945-6800
- Websitehttps://www.inmedpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNS Pharmaceuticals Inc | 0.00 | -13.07m | 2.15m | 4.00 | -- | 0.2006 | -- | -- | -130.83 | -130.83 | 0.00 | 17.25 | 0.00 | -- | -- | 0.00 | -135.60 | -153.00 | -197.11 | -237.57 | -- | -- | -- | -- | -- | -- | 0.0031 | -- | -- | -- | 21.18 | -- | -26.93 | -- |
| Cardio Diagnostics Holdings Inc | 15.79k | -6.55m | 2.32m | 13.00 | -- | 0.2752 | -- | 146.87 | -4.07 | -4.07 | 0.0097 | 4.61 | 0.0024 | -- | 1.25 | 1,214.62 | -98.75 | -- | -104.31 | -- | -- | -- | -41,495.31 | -- | -- | -440.22 | 0.00 | -- | 104.39 | -- | -0.079 | -- | -- | -- |
| Purminds Enterprises Inc | 0.00 | -77.46k | 2.36m | 0.00 | -- | 0.0654 | -- | -- | -0.1832 | -0.1832 | 0.00 | 0.7646 | 0.00 | -- | -- | -- | -26.19 | -620.48 | -66.38 | -- | -- | -- | -- | -- | -- | -6.29 | 0.00 | -- | -- | -- | -13.29 | -- | -- | -- |
| Artelo Biosciences Inc | 0.00 | -12.49m | 2.42m | 5.00 | -- | -- | -- | -- | -20.88 | -20.88 | 0.00 | -0.407 | 0.00 | -- | -- | 0.00 | -219.08 | -- | -427.33 | -- | -- | -- | -- | -- | -- | -91.40 | 3.62 | -- | -- | -- | -5.78 | -- | -- | -- |
| Lyra Therapeutics Inc | 600.00k | -32.95m | 2.47m | 30.00 | -- | -- | -- | 4.11 | -23.78 | -23.78 | 0.418 | -2.63 | 0.0098 | -- | -- | 20,000.00 | -53.81 | -64.59 | -67.22 | -76.36 | -- | -- | -5,491.17 | -5,844.58 | -- | -- | -- | -- | -1.54 | -- | -49.07 | -- | 61.78 | -- |
| InMed Pharmaceuticals Inc | 4.51m | -7.66m | 2.56m | 13.00 | -- | 0.2565 | -- | 0.5681 | -4.08 | -4.08 | 1.72 | 3.42 | 0.4577 | 3.09 | 20.23 | -- | -77.84 | -87.37 | -93.34 | -107.49 | 29.73 | -- | -170.07 | -356.16 | 5.30 | -- | 0.00 | -- | 7.50 | -- | -6.34 | -- | -- | -- |
| BioRestorative Therapies Inc | 383.40k | -12.67m | 2.58m | 11.00 | -- | 1.04 | -- | 6.72 | -1.48 | -1.48 | 0.0447 | 0.2766 | 0.0379 | -- | 4.30 | 34,854.55 | -125.35 | -149.02 | -207.73 | -188.71 | 93.34 | -- | -3,304.77 | -11,837.37 | -- | -- | 0.00 | -- | 175.03 | 25.27 | 13.81 | -- | 24.41 | -- |
| Oragenics Inc | 0.00 | -10.90m | 2.74m | 3.00 | -- | 0.2756 | -- | -- | -17.15 | -17.15 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -121.78 | -113.47 | -168.95 | -126.49 | -- | -- | -- | -34,218.60 | -- | -14.92 | 0.0386 | -- | -100.00 | -- | 48.84 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -63.41m | 2.85m | 1.00 | -- | 0.1976 | -- | -- | -45.47 | -45.47 | 0.00 | 1.08 | 0.00 | -- | -- | 0.00 | -702.98 | -- | -1,223.40 | -- | -- | -- | -- | -- | -- | -56.99 | 0.0422 | -- | -- | -- | -2,826.43 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 2.90m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Geovax Labs Inc | 3.35m | -25.31m | 2.91m | 17.00 | -- | 0.4068 | -- | 0.8677 | -49.15 | -49.15 | 5.86 | 4.13 | 0.3759 | -- | 12.25 | 197,268.20 | -283.68 | -128.86 | -377.44 | -172.81 | -- | -- | -754.69 | -1,385.19 | -- | -- | 0.00 | -- | -- | 27.45 | 3.75 | -- | 22.10 | -- |
| Enveric Biosciences Inc | 0.00 | -11.25m | 2.92m | 5.00 | -- | 0.1326 | -- | -- | -94.63 | -94.63 | 0.00 | 15.83 | 0.00 | -- | -- | 0.00 | -212.68 | -146.94 | -262.78 | -198.90 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.16 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Dec 2025 | 280.14k | 9.99% |
| Virtu Americas LLCas of 30 Sep 2025 | 20.37k | 0.73% |
| Jane Street Capital LLCas of 31 Dec 2025 | 11.98k | 0.43% |
| UBS Securities LLCas of 31 Dec 2025 | 377.00 | 0.01% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 300.00 | 0.01% |
| Banque Cantonale Vaudoise (Investment Management)as of 31 Dec 2025 | 6.00 | 0.00% |
| Desjardins Global Asset Management, Inc.as of 31 Dec 2025 | 1.00 | 0.00% |
| AllSquare Wealth Management LLCas of 30 Sep 2025 | 1.00 | 0.00% |
| Desjardins Securities, Inc.as of 31 Dec 2025 | 1.00 | 0.00% |
| Thompson Davis & Co., Inc. (Investment Management)as of 31 Dec 2025 | 0.00 | 0.00% |
